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As many new biologically active chemokines have
been cloned exploring the genomic DNA sequence
database in the vicinity of already known chemokine
sequences without demonstrating their natural ori-
gin, it is important to transfer ®ndings from in vitro
experiments with chemokines into the in vivo situ-
ation. With respect to eosinophils and ®broblasts that
play an important part in the pathogenesis of allergic
and autoimmune diseases, the role of the recently
discovered members of the eotaxin family, eotaxin-2
and eotaxin-3, is not really understood. In order to
elucidate the origin and biologic potency of the
eotaxin family this study was performed.
Conventional reverse transcription±polymerase chain
reaction analysis was suitable to detect mRNA for
eotaxin and eotaxin-3 but not for eotaxin-2 in der-
mal ®broblasts. In contrast to conventional reverse
transcription±polymerase chain reaction, LightCycler
analysis revealed that dermal ®broblasts constitu-
tively expressed mRNA not only for eotaxin and
eotaxin-3 but also for eotaxin-2. Moreover, with this
technique we investigated mRNA expression levels
after stimulation of ®broblasts with interleukin-4 and
interleukin-4 plus tumor necrosis factor-a: the rank
order of expression levels within the eotaxin
family was eotaxin > eotaxin-3 > eotaxin-2. To
address the question of the ef®cacy of eotaxin-3,
we compared its activity with eotaxin, eotaxin-2,
monocyte chemotactic protein-3, monocyte chemo-
tactic protein-4, and RANTES in different test sys-
tems for eosinophils. The ef®cacy of the CC
chemokines at equimolar concentrations with
respect to the chemotactic response of human
eosinophils was eotaxin-3 = eotaxin = eotaxin-
2 > RANTES > monocyte chemotactic protein-4.
The rank order of activity with respect to actin poly-
merization and release of toxic reactive oxygen spe-
cies was eotaxin-3 = eotaxin = eotaxin-2 and
eotaxin = eotaxin-2 > eotaxin-3 = monocyte chemo-
tactic protein-3 = monocyte chemotactic protein-
4 = RANTES, respectively. This study indicated a
distinct pro®le in expression levels of the members
of the eotaxin family in dermal ®broblasts. Indeed,
all three eotaxin ligands demonstrated activation of
human eosinophils with similar ef®cacies for chemo-
taxis, cytoskeletal rearrangements, activation of Gi
proteins and transients of [Ca2+]i, but a distinct
pro®le of activity with respect to the binding to
CCR3 and the release of toxic reactive oxygen
species. These ®ndings may help to understand
further the role of CC chemokines in ®broblast/eosi-
nophil activation, which is of interest particularly in
allergic and autoimmune diseases. Keywords: chemo-
kine receptor/chemokine/eosinophils/eotaxin/®broblasts. J
Invest Dermatol 116:498±505, 2001
H
uman eosinophils and ®broblasts play an important
part in the pathogenesis of autoimmune diseases and
hematologic disorders such as Hodgkin's disease
(Jundt et al, 1999; Levi-Schaffer et al, 1999;
SchroÈder and Mochizuki, 1999; Teruya-Feldstein
et al, 1999). The accumulation of eosinophils in tissues is regulated
by locally generated chemokines and cytokines (Elsner and Kapp,
2000). Recent studies clearly indicate that eosinophils are
responsible for tissue damage of the host due to the release of
toxic reactive oxygens and cationic toxic proteins; however,
previous studies revealed a new role of eosinophils due to their
capacity to liberate cytokines (Levi-Schaffer et al, 1999; Woerly
et al, 1999) and chemokines (Youse® et al, 1995; Ying et al, 1996)
acting on lymphocytes, monocytes, and ®broblasts.
Chemokines and their receptors play an important part within
many processes in the immunosurveillance as well as in traf®cking,
recruitment and activation of speci®c cell populations during
in¯ammation. They can be divided into ®ve classes, which can be
distinguished on the basis of the arrangement of the amino acid
cysteine in the amino-terminal region: CXC chemokines, CC
chemokines, C chemokines, CX3C chemokines, and virus-
encoded chemokines (Wells et al, 1999). Initially, it was generally
accepted that the chemokine subclasses differ in their biologic
activity to stimulate different kinds of leukocytes, so that CXC
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chemokines are mediators of acute in¯ammation through neu-
trophil activation whereas the CC chemokines mediate chronic
in¯ammation by attracting leukocytes such as eosinophils, mono-
cytes, lymphocytes, basophils, and dendritic cells (Wells et al, 1999;
Elsner and Kapp, 2000). This paradigm, however, has recently been
shown to have exceptions: for example CXCR3 is expressed on
activated T cells (Loetscher et al, 1996).
Even though there are no speci®c chemokines for the different
cell types, one group of chemokines, the eotaxin family, has a
preference in the activation of eosinophils via a single CC
chemokine receptor, the CCR3. After identi®cation of eotaxin
as a relatively selective chemokine for eosinophils (Jose et al, 1994;
Ponath et al, 1996), eotaxin-2 was cloned and showed chemotactic
activity for eosinophils in a similar range as eotaxin (Forssmann
et al, 1997; White et al, 1997). More recently a new member of the
eotaxin family, eotaxin-3, has been cloned from two groups
independently (Kitaura et al, 1999; Shinkai et al, 1999). The
homology of identical amino acids between eotaxin-2 and eotaxin
makes up only 39% (Forssmann et al, 1997), between eotaxin-3 and
eotaxin 37%, and between eotaxin-3 and eotaxin-2 34% (Shinkai
et al, 1999). Although the homology in identical amino acids of the
eotaxin family is low, a characteristic feature of these chemokines is
their close evolutionary and genetic relationship and their speci®c
activity via the CCR3 only (Forssmann et al, 1997; White et al,
1997; Elsner et al, 1998; Kitaura et al, 1999; Shinkai et al, 1999).
Thus, the eosinophil selective nature of the eotaxin family is a
consequence of its exclusive use of CCR3 and the relatively unique
expression of CCR3 on eosinophils. More recently, CCR3
receptor recycling in eosinophils could be observed after stimula-
tion with CCR3 ligands (Zimmermann et al, 1999; Elsner et al,
2000).
As most of the identi®ed chemokines, e.g., eotaxin-2
(Forssmann et al, 1997; White et al, 1997; Nomiyama et al, 1998)
and eotaxin-3 (Kitaura et al, 1999), are found by screening the
genomic DNA sequence database in the vicinity of already known
chemokine sequences, the in vivo role of these chemokines is
considered controversial. Even though eotaxin-2 has been identi-
®ed by reverse transcription±polymerase chain reaction (PCR), in
situ hybridization, and immunohistochemistry in the tissue of nasal
polyps (Jahnsen et al, 1999), asthmatic lung ± predominantly in
cytokeratin-positive epithelial cells, CD31+ endothelial cells, and
CD68+ macrophages (Ying et al, 1999a) ± and allergen-induced,
late-phase allergic reactions in the skin of human atopic subjects
(Ying et al, 1999b), eotaxin-2 could not yet be identi®ed on the
single cell type level. Moreover, mRNA for eotaxin-3 could be
detected in human umbilical vascular endothelial cell line (Shinkai
et al, 1999) and in the tissue of human heart and ovary (Kitaura
et al, 1999); however, no cell type could be identi®ed as a natural
source of eotaxin-3 so far. In contrast to eotaxin-2 and eotaxin-3,
mRNA for eotaxin could be identi®ed in human dermal and lung
®broblasts (Bartels et al, 1996; SchroÈder and Mochizuki, 1999). In
addition, large quantities of eotaxin protein are released by dermal
®broblasts, the amount being nearly 10,000-fold that of lung
epithelial cells, following stimulation with interleukin (IL) -4 and
tumor necrosis factor (TNF)-a (SchroÈder and Mochizuki, 1999)
(and own unpublished results).
To get more insight into the in vivo role of the eotaxin family in
the in¯ammatory response, we investigated dermal ®broblasts as a
possible natural source of eotaxin, eotaxin-2 and the recently
discovered third member of the eotaxin family, eotaxin-3. As the
rank order of activity within the eotaxin family in the activation of
human eosinophils is discussed controversially and reported only for
the chemotactic response, we investigated chemotaxis-related
events, such as actin polymerization and the release of reactive
oxygen species. For this purpose eosinophil effector functions,
relevant for their in vivo role, were analyzed in response to the
speci®c CCR3 ligands eotaxin, eotaxin-2, eotaxin-3, and in some
experiments compared with RANTES, monocyte chemotactic
protein (MCP) -3 and MCP-4.
MATERIALS AND METHODS
Chemokines and anti-CCR3 monoclonal antibody (MoAb)
Eotaxin, eotaxin-2, eotaxin-3, RANTES, MCP-3, and MCP-4 were a
kind gift from Dr. Amanda Proudfoot (Serono Pharmaceutical Research
Institute, Geneva, Switzerland) or obtained from Peprotech (London,
U.K.). The anti-CCR3 MoAb, clone 61828.111, was obtained from
R&D Systems (Wiesbaden, Germany).
Eosinophil isolation Human granulocytes were isolated from heparin-
anticoagulated venous blood from normal nonatopic healthy donors
using Ficoll (Pharmacia, Freiburg, Germany) density gradient
centrifugation as described previously (Elsner et al, 2000). For further
puri®cation granulocytes were resuspended in HEPES-buffered Hanks'
balanced salt solution (Gibco, Grand Island, NY), pH 7.4 containing
1 mg per ml bovine serum albumin. Eosinophils were puri®ed by
negative selection with anti-CD16 MoAb (clone 3G8, Immunotech,
Hamburg, Germany) coated Dynabeads M-450 (Dynal, Hamburg,
Germany) as described previously (Elsner et al, 2000). The resulting
eosinophil purity was 99% determined by microscopic examination with
Kimura staining and ¯ow cytometric analysis (FACScan, Becton
Dickinson, Heidelberg, Germany) as described previously (Elsner et al,
2000).
mRNA analysis of CC chemokines in human dermal ®bro-
blasts Clinical normal human skin was obtained from plastic breast
surgery. Dermis and epidermis were separated by overnight incubation in
dispase (2.4 U per ml, Roche Molecular Biochemicals, Mannheim,
Germany). The epidermis was detached from the dermis with ®ne
forceps. Thereafter, dermis was incubated in RPMI medium (Gibco)
containing 0.1% collagenase and 0.1% hyaluronidase. After ®ltration
through a sterile sieve, the harvested ®broblasts were cultured in
®broblast growth medium (Promo Cell, Heidelberg, Germany) as
described previously (Petering et al, 1998). Fibroblasts between the third
and fourth passage were cultured and stimulated for 24 h in ®broblast
growth medium alone or in medium containing either 100 ng per ml
IL-4, 30 ng per ml TNF-a, or 100 ng per ml IL-4 plus 30 ng per ml
TNF-a (R&D Systems, Wiesbaden, Germany), respectively. Poly(A+)
RNA was isolated using a mRNA isolation kit (Roche Molecular
Biochemicals). The method relies on base-pairing between the poly(A+)
residues at the 3¢-ends of the mRNA and biotin-labeled oligo(dT)20
probe, which itself can be used for immobilization on streptavidin-coated
magnetic particles. Non-adenylated RNA species are not bound and
easily washed off. The bound mRNA is eluted from the solid support by
lowering the salt concentration. The isolated mRNA was used for
cDNA synthesis with the ®rst strand cDNA synthesis kit (Roche
Molecular Biochemicals) following the instruction manual as described
previously (Petering et al, 1998). Speci®c PCR primers that do span
intronic sequences for human mRNA of eotaxin, eotaxin-2, and
eotaxin-3 were designed and conventional PCR was performed under
primer-speci®c conditions (Table I). PCR samples were run on a 2%
agarose gel stained with 0.2 mg ethidium bromide per ml, and the PCR
products were visualized with ultraviolet light and photographed. To
exclude the possibility of genomic DNA contamination PCR was carried
out using the isolated mRNA without performing a reverse
transcription. No signal and, therefore, no contamination could be
detected.
Rapid-cycle PCR with the LightCycler system In addition to
conventional PCR, LightCycler PCR was carried out by rapid-cycling
in glass capillaries with a reaction volume of 20 ml using the LightCycler
Instrument. PCR was performed with LightCycler-DNA Master SYBR
Green I as a ready-to-use reaction mix (Roche Molecular Biochemicals)
as described previously (Petering et al, 2000). This buffer contains
nucleotides, Taq DNA-polymerase, reaction buffer, SYBR Green I dye,
and 10 mM Mg2+. Template DNA, primers (2.0 mM), sterile H2O, and
additional MgCl2 (the ®nal Mg
2+ concentration was adjusted to 3 mM)
had to be added. SYBR Green is a double-strand DNA speci®c dye,
which binds to the ampli®ed PCR products, and the amplicon can be
detected by its ¯uorescence. The following experimental protocol was
adapted to use eotaxin, eotaxin-2, and eotaxin-3: After an initial
denaturation step at 95°C for 30 s, 40 cycles of ampli®cation were
performed. Beginning with a denaturation step at 95°C, followed by
primer speci®c annealing (Table I), the elongation was carried out at
72°C with an amplicon-depending incubation time (t = (bp 4 25)
seconds). SYBR Green I ¯uorescence was detected at the end of each
elongation cycle immediately before melting temperature of the speci®c
PCR product was reached. Therefore, no unspeci®c ¯uorescence due to
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primer dimers was detected and the amount of speci®c PCR product
formed during that cycle was monitored. After the end of ampli®cation,
a ®nal melting curve was recorded by cooling the sample to 65°C at a
rate of 20°C per s, maintaining 65°C for 15 s, and then heating slowly at
0.2°C per s up to 95°C with continuos measurement of ¯uorescence. At
the end of each run a melting curve analysis on the ampli®cation
reaction was performed to increase the speci®city and sensitivity of
SYBR Green I detection. The ¯uorescence signal (F) was plotted against
temperature (T) to produce melting curves for each sample (F v T).
Melting curves were then converted to melting peaks by plotting the
negative derivative of the ¯uorescence with respect to temperature
against temperature (± dF/dT v T). Thus, each speci®c PCR product
produced a product-speci®c signal that results in a product-speci®c
melting peak. Moreover, the LightCycler can quantify nucleic acids in
unknown samples by direct comparison with standards that are ampli®ed
in parallel reactions. The standards used in this experiment were obtained
from a serial dilution of cDNA from medium-stimulated ®broblasts. The
instrument generates a standard curve by plotting the standard
concentrations v the crossing points, which are de®ned as the
intersection between each ¯uorescence curve and the crossing line. By
setting a crossing line, the user causes data acquired before the log-linear
phase to be discarded. Finally, the standard curve allows calculation of
the template concentrations and a number of gene copies in the
unknowns using LightCycler software.
Automated sequencing of PCR product The PCR product
obtained by LightCycler predicted for eotaxin-2 was puri®ed using High
Pure PCR Product Puri®cation Kit and automatically sequenced by
GATC GmbH (Konstanz, Germany, http://www.gatc.de). Nucleotide
sequence data of the sequenced PCR product was compared with the
published mRNA sequence of eotaxin-2 mRNA (accession number
U85768).
Chemotaxis assay Chemotactic activity of eosinophils was performed
as described previously using the modi®ed Boyden chamber technique
(Elsner et al, 1996a). Brie¯y, Boyden chambers (Nuclepore GmbH,
TuÈbingen, Germany) were ®lled with the stimuli and covered with
polycarbonate ®lters (pore size, 3 mm; Nuclepore). One hundred
microliters of a human eosinophil suspension at a concentration of
5 3 105 per ml was added to each chamber. After incubation for 1 h at
37°C migrated cells in the lower part of the Boyden chambers were
lyzed by adding 0.1% Triton X-100, and b-glucuronidase activity in the
lysates was determined photometrically using p-nitrophenyl b-D-
glucuronide as a substrate (all by Sigma, Deisenhofen, Germany). For
calculation of the number of migrated cells, equivalent to b-
glucuronidase activity determined in the lower part of the Boyden
chamber, values were calculated by a computer-assisted technique from a
standard curve using known numbers of unchallenged eosinophils.
Chemotactic activity was expressed as the chemotactic index: ratio of the
number of migrating cells in the presence of stimulus/migrating cells in
presence of medium.
Assessment of actin polymerization in eosinophils
Nitrobenzoxadiazole (NBD) -phallacidin (Molecular Probes, Eugene,
OR) staining of granulocytes was carried out by modi®cation of the
method described by Howard and Meyer (1984; Elsner et al, 1996b).
Brie¯y, puri®ed cells were re-suspended at a concentration of 2 3 105
cells per ml in phosphate-buffered saline buffer lacking Ca2+ and
stimulated with the indicated chemotaxin or phosphate-buffered saline
buffer at 37°C. Following stimulation, cells were ®xed using 3.7%
formaldehyde for 60 min. Lysophosphatidylcholine (20 mg per ml) and
3.7 3 10±7 M NBD-phallacidin were added to the sample and incubated
for a period of 60 min in the dark. NBD-phallacidin-stained cells were
analyzed on a Becton Dickinson FACScan with a linear ¯uorescence
channel (FL1) where the ¯uorescence is proportional to F-actin content
(Howard and Meyer, 1984). Relative F-actin content is expressed as the
ratio of the mean channel ¯uorescence (= integrated ¯uorescence)
between chemotaxin-stimulated and nonstimulated cells (Elsner et al,
1996b).
Measurement of [Ca2+]i in spectro¯uorometry Eosinophils were
loaded with 2 mM Fura-2 (Molecular Probes) and [Ca2+]i was measured
at 37°C in an Aminco Bowman Series 2 spectro¯uorometer (SLM-
Aminco, Urbana, IL) as described previously (Elsner et al, 2000).
Absolute [Ca2+]i was calculated automatically by AB2 series 2 software
(SLM-Aminco) according to the following equation described by
Grynkiewicz et al (1985): [Ca2+]i = Kd 3 (R ± Rmin)/(Rmax ± R) 3
(Sf2/Sb2). Data are expressed as the original plot (Elsner et al, 2000).
Lucigenin-dependent chemiluminescence Lucigenin-dependent
chemiluminescence was measured using a single-photon imaging system
with a two-dimensional photon counting system (MTP reader,
Hamamatsu Photonics, Herrsching, Germany) as described elsewhere
(Elsner et al, 2000). This system allows the measurement and analysis of
96 wells simultaneously. In brief, eosinophils were suspended to a density
of 5 3 104 cells per ml in Hanks' balanced salt solution + bovine serum
albumin, respectively, containing 200 mM lucigenin (Sigma). Aliquots
(100 ml) containing 5 3 103 eosinophils, respectively, were placed into
¯at-bottomed white microtiter plates (Micro¯uor, Dynatech,
Denkendorf, Germany). Cells were stimulated by the indicated stimuli
and medium. Measurements were performed in triplicate at 37°C.
Integral counts from 0 to 60 min incubation intervals after addition of
the stimuli to the cell sample were measured and expressed as intensity
integral counts. Data are expressed as the original plots or ratio between
stimulus-induced intensity integral counts and medium-induced intensity
integral counts (Elsner et al, 2000).
Toxin treatment Pertussis toxin and pertussis toxin B oligomer (b-
subunit) (Calbiochem Novabiochem, San Diego, CA) treatment was
performed by incubation of 1 3 106 cells per ml for 120 min at 37°C
with and without 2 mg per ml pertussis toxin as described elsewhere
(Elsner et al, 2000). The cells were then washed and resuspended in test
medium. The B oligomer of pertussis toxin that is responsible for the
binding of pertussis toxin and insertion of the A promoter into the cell
had no effect. Viability of eosinophils after toxin treatment was more
than 95% as assessed by propidium iodide (Molecular Probes) staining in
¯ow cytometry.
Statistical analysis Statistical analysis was performed using the
SigmaStat version 2.0 statistical package (Jandel, Erkrath, Germany).
Unless otherwise stated, the data in the text and ®gures are expressed as
mean 6 SEM. Comparison of the means of more than two groups were
done by one-way ANOVA. When the differences in the mean values of
the groups showed a signi®cant difference, pairwise comparison was
performed using Student's t test or Wilcoxon signed rank test. p < 0.05
was considered to be signi®cant.
RESULTS
Human dermal ®broblasts express mRNA not only for
eotaxin but also for eotaxin-2 and eotaxin-3 In order to
investigate whether dermal ®broblasts are able to express mRNA
Table I. Oligonucleotide primers, conditions, and PCR product sizes for chemokine cDNAs





Eotaxin TGAAGCTTGGGCCAGCTTCTGTCCCAACC 56 216 U46573
TGGTCGACTGGAGTTGGAGATTTTTGGTC
Eotaxin-2 CCATAGTAACCAGCCTTC 58 251 U85768
CAGGTTCTTCATGTACCTC
Eotaxin-3 AACTCCGAAACAATTGTGACTCAGCTG 62 152 AB010447
GTAACTCTGGGAGGAAACACCCTCTCC
b-Actin GAAGGTAGTTTCGTGGATGCC 56 221 AB004047
GAGCGGGAAATCGTGCGTGACATT
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for eotaxin-2 and eotaxin-3, human dermal ®broblasts between the
third and the fourth passage were cultured and stimulated for 24 h
with IL-4, TNF-a, IL-4 plus TNF-a, or medium alone.
Conventional reverse transcription±PCR analysis revealed that
dermal ®broblasts constitutively expressed low levels of mRNA for
eotaxin-3 and eotaxin, but not for eotaxin-2 (Fig 1). Moreover,
IL-4 and the combination of IL-4 and TNF-a enhanced mRNA
expression for eotaxin-3 and eotaxin (Fig 1).
To exclude the possibility that conventional PCR is not sensitive
enough to detect mRNA for eotaxin-2 in dermal ®broblasts the
highly sensitive method of rapid-cycle PCR with the LightCycler
system was used. Surprisingly, mRNA for eotaxin-2 could be
detected in nonstimulated and cytokine-stimulated dermal ®bro-
blasts as indicated by the melting curves (Fig 2A). Single strand
sequence analysis of the PCR product obtained with LightCycler
showed 99% homology to the published eotaxin-2 mRNA
nucleotide sequence (data not shown). To address the question to
how representative cultured ®broblasts are of normal skin
®broblasts, we studied freshly isolated ®broblasts and ®broblasts in
earlier passages for their eotaxin-2 and eotaxin-3 mRNA expres-
sion. We found constitutive expression of mRNA for eotaxin-2
and eoataxin-3 in freshly isolated ®broblasts as well as in ®broblasts
in passage 1 and 2 after isolation (data not shown). As the
LightCycler method is also suited to quantify mRNA content, we
compared the expression of mRNA for eotaxin, eotaxin-2, and
eotaxin-3 in medium and cytokine-stimulated dermal ®broblasts.
The LightCycler can quantify nucleic acids in unknown samples by
direct comparison with standards which are ampli®ed in parallel
reactions (see Materials and Methods). After stimulation with IL-4 or
IL-4 plus TNF-a we could detect an early speci®c ¯uorescence
signal of eotaxin-2 cDNA after 27±30 cycles, whereas after
stimulation with medium or TNF-a alone no ¯uorescence was
seen before the 33rd or 35th cycle, respectively (Fig 2). Moreover,
the ¯uorescence signal for eotaxin-3 increased after 12 cycles
already for IL-4 and IL-4 plus TNF-a, whereas the signal for
medium or TNF-a-stimulated cells increased after 22 cycles.
Comparable results were seen for eotaxin; however, TNF-a alone
Figure 1. Conventional reverse transcription±PCR indicates that
dermal ®broblasts express mRNA for eotaxin-3 and eotaxin, but
not for eotaxin-2. After stimulation of ®broblasts for 24 h with 100 ng
IL-4 per ml, 30 ng TNF-a per ml, 100 ng IL-4 per ml plus 30 ng
TNF-a per ml, or medium alone, mRNA was isolated, and a ®rst-strand
cDNA synthesis was performed. The PCR was conducted with speci®c
primer pairs as indicated in Table I; the graph shows amplicons for the
expected CC chemokines eotaxin (216 bp), eotaxin-2 (251 bp), eotaxin-
3 (152 bp), and b-actin (221 bp) as a positive control. The amplicons
were separated electrophoretically in 2.0% agarose gel and stained by
ethidium bromide. Lane L (ladder), 50 bp DNA size marker (bright
band: 350 bp); lane 1, medium; lane 2, IL-4; lane 3, TNF-a; lane 4, IL-4
plus TNF-a. One representative experiment of ®ve is shown.
Figure 2. LightCycler PCR analysis detects mRNA not only for eotaxin and eotaxin-3, but also for eotaxin-2 in dermal ®broblasts.
Human dermal ®broblasts from the same donor shown in Fig 1 were incubated for 24 h with 100 ng IL-4 per ml, 30 ng per ml, 100 ng IL-4 per ml
plus 30 ng TNF-a per ml, or medium alone, mRNA was isolated, and a ®rst-strand cDNA synthesis was performed. The PCR was conducted with
speci®c primer pairs as indicated in Table I. LightCycler analysis has been carried out as described in detail in Materials and Methods. (A) The graphs
show the calculated ®rst derivate of the run data as temperature v ±dF/dT. The data displays ``melting peaks'' for each of the ampli®ed products
including primer dimers. (B) The graphs show the ¯uorescence v cycle number during the ampli®cation phase of eotaxin, eotaxin-2, and eotaxin-3.
One representative experiment of three is shown. The symbols indicate: Medium (ÐÐ), IL-4 (´´´´´´´´´), TNF-a (- - - -), IL-4 plus TNF-a (±´±´±), and
water (± ± ±).
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was also able to upregulate eotaxin mRNA in dermal ®broblasts
(Fig 2). Agarose gel electrophoresis of the samples obtained by the
LightCycler revealed the predicted size for eotaxin, eotaxin-2, and
eotaxin-3 (data not shown). In order to investigate which member
of the eotaxin family shows the highest expression level following
cytokine stimulation, we calculated ratios of gene copies using
LightCycler software. After stimulation of ®broblasts with IL-4 and
IL-4 plus TNF-a, the rank order of expression levels within the
eotaxin family was eotaxin > eotaxin-3 > eotaxin-2. Therefore,
dermal ®broblasts seem to be a physiologic source not only for
eotaxin but also for eotaxin-2 and eotaxin-3.
Eotaxin-3 stimulates chemotaxis of human eosinophils in the
same range as eotaxin and eotaxin-2 As controversial results
have been described for the potency of eotaxin-3 in the stimulation
of eosinophil chemotaxis, we investigated the chemotaxis of
eosinophils in response to different CCR3 ligands. Eotaxin-3
induced a signi®cant concentration-dependent chemotaxis response
in human eosinophils (Fig 3). Maximal chemotaxis response was
reached at 100 ng per ml for eotaxin-3, eotaxin, and eotaxin-2. In
comparison with RANTES, all members of the eotaxin family seem
to be more potent, but this effect was not statistically signi®cant
(Fig 3). A signi®cant difference (p = 0.013) in the chemotactic
potency, however, could be detected in eotaxin-3, eotaxin, and
eotaxin-2 in comparison with MCP-4 (Fig 3). Therefore, the
ef®cacy of the CC chemokines at optimal concentrations with
respect to the chemotactic response of human eosinophils was
eotaxin-3 = eotaxin = eotaxin-2 > RANTES > MCP-4.
Eotaxin-3 induces actin polymerization in human
eosinophils in the same range as eotaxin and eotaxin-2 In
order to ®nd out whether eotaxin-3 was able to activate
chemotaxis-related events, actin polymerization was investigated
using NBD-phallacidin and ¯ow cytometry. Eotaxin-3 induced
rapid actin polymerization reaching maximal F-actin content 30 s
after stimulation and decreased to basal F-actin level after 300 s
(Fig 4). At optimal concentration (1000 ng per ml) eotaxin-3 was
as potent as eotaxin and eotaxin-2 (Fig 4A). Interestingly, whereas
all members of the eotaxin family induced comparable activity of
actin polymerization at 100 ng per ml and 1000 ng per ml, eotaxin-
3 and eotaxin-2 seemed to be more potent than eotaxin at 10 ng
per ml (Fig 4); however, this difference was not signi®cant.
Therefore, the ef®cacy of the CCR3 ligands at optimal
concentration with respect to the actin polymerization in human
eosinophils was eotaxin-3 = eotaxin = eotaxin-2.
Eotaxin-3 is less potent than eotaxin and eotaxin-2 in the
release of toxic reactive oxygen species from human
eosinophils In a previous study we were able to demonstrate
that eotaxin and eotaxin-2 have the same ef®cacy in the activation
of the respiratory burst in human eosinophils. Now we compared
the effect of eotaxin-3 with eotaxin and eotaxin-2 in the release of
reactive oxygen species using lucigenin-dependent chemi-
luminescence. As shown in Fig 5(A), eotaxin-3 induced a
concentration-dependent release of reactive oxygen species from
eosinophils. The response upon stimulation with eotaxin-3 was
rapid, reaching maximum values within 2 min at 37°C and was
similar to the reaction of eosinophils, which were exposed to
eotaxin and eotaxin-2 (Fig 5B); however, in comparison with
eotaxin-2 and eotaxin-3 at optimal concentration (1000 ng per ml)
eotaxin-3 (Fig 5A) was less potent than eotaxin and eotaxin-2
(p = 0.020). In comparison with the other CCR3 ligands, MCP-3,
MCP-4, and RANTES, eotaxin-3 showed the same ef®cacy
(Fig 5A). Pretreatment of eosinophils with pertussis toxin, which
Figure 3. Eotaxin stimulates chemotaxis of human eosinophils in
the same range as eotaxin and eotaxin-2. Eosinophils (n = 8) were
stimulated with the indicated CC chemokine. The chemotactic activity
was measured using the modi®ed Boyden chamber technique and
expressed as the chemotactic index: quotient of the number of migrating
cells in presence of stimulus/migrating cells in the presence of medium.
*p = 0.013 compared with MCP-4 (Student's t test).
Figure 4. Eotaxin-3 induces actin polymerization in human
eosinophils in the same range as eotaxin and eotaxin-2.
Eosinophils were stimulated with 1000 ng per ml (A), 100 ng per ml
(B), and 10 ng per ml (C) of eotaxin-3, eotaxin, and eotaxin-2. F-actin
content in eosinophils was measured using NBD-phallacidin staining and
¯ow cytometry. Data (n = 8) shows relative F-actin content at different
points of time after CC chemokine stimulation. SEM have been omitted
for clarity.
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adenosine diphosphate-ribosylates Gi proteins, inhibited the release
of reactive oxygen species in response to eotaxin-3 to the same
extent as eotaxin-2 and eotaxin (Fig 5B). Therefore, the ef®cacy of
the CCR3 ligands at optimal concentration with respect to the
release of toxic reactive oxygen species was eotaxin = eotaxin-
2 > eotaxin-3 = MCP-3 = MCP-4 = RANTES.
Eotaxin-3-induced [Ca2+]i transients in human eosinophils
are blocked by an anti-CCR3 MoAb As most of the recent
eotaxin-3 ligand experiments have been performed on cell lines
stably transfected with CCR3, we investigated eotaxin-3/CCR3
interaction on human eosinophils. For this purpose, intracellular
calcium transients were measured using Fura-2 and
spectro¯uorometry. Preincubation of human eosinophils with the
anti-CCR3 MoAb, 61828.111, completely inhibited the calcium
response to eotaxin-3 (Fig 6A). To investigate further whether
eotaxin-3 activates eosinophils via CCR3 cross-desensitization
experiments with eotaxin and eotaxin-2 were performed. At
equimolar concentrations eotaxin-3 induced an almost complete
desensitization to eotaxin (Fig 6E) and a complete desensitization
to eotaxin-2 (Fig 6F). In the vice versa experiments, eotaxin
(Fig 6G) completely and eotaxin-2 (Fig 6D) almost completely
desensitized eosinophils to eotaxin-3. Therefore, eotaxin-3-
induced calcium signaling is regulated speci®cally via CCR3;
however, the differences in the cross-desensitization experiments
indicate a different af®nity of eotaxin-3, eotaxin, and eotaxin-2 to
CCR3 on human eosinophils.
DISCUSSION
The chemokine system has been de®ned as an extremely redundant
system, with multiple ligand binding patterns for several receptors
and certain ligands that are able to activate several receptors
(Proudfoot et al, 1999; Wells et al, 1999); however, it must be
remembered that the discovery of many new chemokines are due
to exploring the genomic DNA sequence database in the vicinity of
already known chemokine sequences (Wells and Peitsch, 1997). To
this end, many new biologically active chemokines have been
cloned without demonstrating their natural origin. Therefore, it is
very important to transfer ®ndings from experiments with
chemokines that have been performed mostly in vitro to the in vivo
situation. With respect to eosinophils, the role of the recently
discovered members of the eotaxin family, eotaxin-2 and eotaxin-
3, is not really understood. In order to elucidate the origin and
biologic potency of the eotaxin family this study was performed.
In recent studies dermal and lung ®broblasts could be identi®ed
as major sources of eosinophil-activating CC chemokines such as
Figure 5. Eotaxin-3 is less potent than eotaxin and eotaxin-2 in
the release of toxic reactive oxygen species from human
eosinophils. The release of reactive oxygen species release was measured
using lucigenin-dependent chemiluminescence. (A) Human eosinophils
were stimulated with different concentrations of the indicated CC
chemokine. Data (n = 8) are expressed as relative reactive oxygen species
(ROS) release that is expressed as the ratio of stimulus-stimulated and
medium-stimulated cells. *p = 0.020 for eotaxin-3 compared with
eotaxin and eotaxin-2 (Wilcoxon signed rank test). (B) Eosinophils were
preincubated with medium and 2 mg per ml pertussis toxin, respectively,
as described in Materials and Methods. Viability of eosinophils after toxin
treatment was more than 95% as assessed by propidium iodide staining in
¯ow cytometry. Data are shown as the time course of reactive oxygen
species release following stimulation with eotaxin-3, eotaxin, eotaxin-2,
and medium. One representative experiment of ®ve is shown using
lucigenin-dependent chemiluminescence.
Figure 6. Eotaxin-3 acts via the CC chemokine receptor CCR3.
Spectro¯uorometric measurement of [Ca2+]i in Fura-2-loaded human
eosinophils was carried out as described in Materials and Methods. (A, B)
Eosinophils were preincubated for 5 min with the anti-CCR3 MoAb,
7B11, and subsequently stimulated with eotaxin-3 (100 ng per ml) or
eotaxin (100 ng per ml) and C5a (100 ng per ml) as a positive control.
(C±F) Cross-desensitization experiments were carried out using
spectro¯uorometric measurement of [Ca2+]i in Fura-2-loaded
eosinophils. All chemokines were used at the same concentrations
(100 ng per ml). One representative experiment of four is shown.
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RANTES (Sticherling et al, 1995), eotaxin (Bartels et al, 1996), and
MCP-4 (Petering et al, 1998). Moreover, eotaxin seems to play an
important part in ®broblast/eosinophil interaction in the nodular
sclerosis subtype of Hodgkin's disease (Jundt et al, 1999; Levi-
Schaffer et al, 1999; Teruya-Feldstein et al, 1999). To address the
question whether the recently cloned CC chemokines, eotaxin-2
and eotaxin-3 are also expressed in vivo like their counterpart
eotaxin, we investigated dermal ®broblasts for the expression of
mRNA for eotaxin-2 and eotaxin-3. Reverse transcription±PCR
analysis using the LightCycler has shown that mRNA not only for
eotaxin but also for eotaxin-2 and eotaxin-3 is constitutively
expressed by dermal ®broblasts. The Th2 like cytokine IL-4 by
itself and in combination with the proin¯ammatory cytokine TNF-
a upregulated the expression of mRNA for all members of the
eotaxin family. This observation is in contrast to a previous study in
which dermal ®broblasts were not able to express mRNA for
eotaxin-2 (Teran et al, 1999). This might be due to differences in
the technical approach, as Teran et al used conventional reverse
transcription±PCR. In our study we were able to detect mRNA
for eotaxin-2 with the LightCycler technique but not with
conventional reverse transcription±PCR. Sequence analysis of the
PCR product obtained by LightCycler showed 99% homology to
the published eotaxin-2 nucleotide sequence.
In recent reports mRNA for eotaxin-3 could be detected in
tissue samples of the heart and ovary (Kitaura et al, 1999) as well as
in a IL-4-stimulated human umbilical vascular endothelial cell line
(Shinkai et al, 1999). Additionally, certain studies described detec-
tion of eotaxin-2 in the tissue of nasal polyps (Jahnsen et al, 1999),
asthmatic lung (Ying et al, 1999a), and allergen-induced, late-phase
allergic reactions in the skin of human atopic subjects (Ying et al,
1999a). The authors in these studies, however, investigated tissue
samples using immunohistochemistry and in situ hybridization, but
not highly puri®ed cell types such as macrophages and epithelial
cells. In contrast to the latter studies, we could clearly demonstrate
in our study on a single cell level that dermal ®broblasts represent a
natural source not only for eotaxin but also for eotaxin-2 and
eotaxin-3. We were able to reveal a distinct pro®le of mRNA
expression levels. After stimulation of ®broblasts with IL-4 and IL-4
plus TNF-a, the rank order of expression levels in the eotaxin
family was eotaxin > eotaxin-3 > eotaxin-2. Although only eo-
taxin could be detected on the protein level in large amounts so far
(SchroÈder and Mochizuki, 1999), it could not be ®nally concluded
from our study which member of the eotaxin family is most
relevant in vivo.
In recent studies, there were considerable discrepancies in the
reported relative potency and ef®cacy of CCR3 ligands such as
eotaxin, eotaxin-2, eotaxin-3, RANTES, MCP-3, and MCP-4 on
human eosinophils. In one study (Stellato et al, 1997) the rank
order of MCP-4 > RANTES > eotaxin was reported for both
potency and ef®cacy on eosinophils, whereas a different study
(White et al, 1998) concluded a rank order of MCP-
4 > eotaxin > RANTES for potency and eotaxin > MCP-
4 > RANTES for ef®cacy. In yet another report (Garcia-Zepeda
et al, 1996) the potencies for these chemokines were reported as
RANTES > eotaxin = MCP-4 for potency and
eotaxin > RANTES = MCP-4 for ef®cacy. In our studies we
found different rank orders of CC chemokines for the potency and
ef®cacy depending on eosinophil effector function (Elsner et al,
1996a, 1998, 2000; Petering et al, 1998).
Controversial reports exist for the potency of the recently
discovered chemokine eotaxin-3: Shinkai et al (1999) demonstrated
in three different experiments that eotaxin-3 was more potent than
eotaxin with respect to the in vitro chemotactic activity of human
eosinophils. In contrast, Kitaura et al (1999) demonstrated in one
representative experiment of two that eotaxin-3 was 10-fold less
active than eotaxin and not able to induce a signi®cant chemotactic
response for eosinophils before 1 mM. Both groups, however,
investigated only chemotaxis of eosinophils in response to eotaxin-
3 and eotaxin in a small number of experiments that restricted the
assessment of the biologic potency.
To address the question of the potency and ef®cacy of eotaxin-3
more directly, we compared its activity with that of eotaxin,
eotaxin-2, MCP-3, MCP-4, and RANTES in different test
systems for eosinophils. The ef®cacy of the CC chemokines at
equimolar concentrations with respect to the chemotactic response
of human eosinophils was eotaxin-3 = eotaxin = eotaxin-
2 > RANTES > MCP-4. In order to investigate chemotaxis-
related events, actin polymerization, which represents a prerequisite
of the cell migratory response as well as the transport of intracellular
proteins (Elsner and Kapp, 2000) was assessed. In this test system,
again, eotaxin-3 was as potent as eotaxin and eotaxin-2. As the
release of toxic reactive oxygen species by eosinophils is one of the
mechanisms responsible for tissue damage of the host (Elsner and
Kapp, 2000), we compared the potency of eotaxin-3 with that of
other CC chemokines. Interestingly and contrary to chemotaxis
and actin polymerization of eosinophils, eotaxin-3 was less potent
in the release of reactive oxygen species than eotaxin and eotaxin-2.
The range of ef®cacy of the CCR3 ligands at equimolar
concentrations with respect to the release of toxic reactive oxygen
species was eotaxin = eotaxin-2 > eotaxin-3 = MCP-3 = MCP-
4 = RANTES. The discrepancies in previous studies concerning
the ef®cacy of chemokines on eosinophils are likely attributable to
few numbers of experiments, technical issues such as differences in
assay formats, sources of laboratory materials and supplies, and the
chemokine source as well as a donor to donor variability (Garcia-
Zepeda et al, 1996; Stellato et al, 1997; White et al, 1998; Kitaura
et al, 1999; Shinkai et al, 1999). In the study presented here, all
members of the eotaxin family are potent activators of eosinophil
effector functions with a clearly distinct pro®le of activity
depending on the cell function. It is tempting to speculate that
the higher ef®cacy of the eotaxin family on eosinophil chemotaxis
might be due to its higher af®nity to its receptor, CCR3, than the
af®nity of the other ligands RANTES, MCP-3, and MCP-4.
In recent reports eotaxin-3 has been shown to be a speci®c
ligand for CCR3 but not for other chemokine receptors. As most
of the studies were performed on chemokine receptor transfected
cell lines (Kitaura et al, 1999), we addressed the question whether
eotaxin-3 activates eosinophils via the CCR3. Recently, desensi-
tization experiments between eotaxin-3, eotaxin-2, and eotaxin in
eosinophils gave evidence that all members of the eotaxin family act
via the CCR3 (Shinkai et al, 1999). In our cross-desensitization
experiments we were able to con®rm these results; however, at
equimolar concentrations we found complete cross-desensitization
between eotaxin and eotaxin-3, as well as between eotaxin-3 and
eotaxin-2, but only incomplete cross-desensitization between
eotaxin-3 and eotaxin as well as between eotaxin-2 and eotaxin-
3. As desensitization experiments represent only an indirect way of
investigating receptor usage, we assessed the effect of an anti-
CCR3 MoAb, in eosinophil [Ca2+]i release following stimulation
with eotaxin-3. This anti-CCR3 MoAb completely blocked
[Ca2+]i transients in human eosinophils; therefore, eotaxin-3 is a
speci®c ligand for CCR3 on human eosinophils. In addition,
according to the results of the cross-desensitization experiments the
rank order of af®nity to the CCR3 within the eotaxin family was
eotaxin > eotaxin-3 > eotaxin-2. This hypothesis is supported by
competitive binding experiments, in which a 10-fold higher
concentration of eotaxin-3 compared with eotaxin is required for
the inhibition of 125I-eotaxin binding to eosinophils (Shinkai et al,
1999).
This study addresses and clari®es the question of the biologic role
and signi®cance of eosinophil activating chemokines, particularly
the CCR3 speci®c family of eotaxin. Besides eotaxin, eotaxin-2,
and eotaxin-3 could be detected on an mRNA level in dermal
®broblasts. We could demonstrate a distinct pro®le in expression
levels of the members of the eotaxin family in dermal ®broblasts.
Indeed, all three eotaxin ligands demonstrate activation of human
eosinophils with similar ef®cacies for chemotaxis, cytoskeletal
rearrangements, activation of Gi proteins and transients of [Ca
2+]i,
but a distinct pro®le of activity with respect to the binding to
CCR3 and the release of toxic reactive oxygen species. As
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differential traf®cking pathways of chemokine receptors after
activation may be a very important mechanism of speci®city in
this highly redundant system we could demonstrate the major role
of eotaxin, eotaxin-2, and eotaxin-3 in the activation of human
eosinophils. These ®ndings may help to understand further the role
of CC chemokines in ®broblast/eosinophils activation, which is of
particular interest in allergic and autoimmune diseases.
This work was supported by a grant from the Deutsche Forschungsgemeinschaft (EL
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